GlassScriptPhysician profile
William J Gramann
NPI 1093798779
$2,541.19
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,143 · 2020: $378 · 2021: $21.00.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $369.57 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $271.46 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $243.28 | 2019-2020 | |
| Lilly USA, LLC | $184.71 | 2019-2020 | |
| Pfizer INC. | $182.15 | 2019 | |
| Glaxosmithkline, LLC. | $157.85 | 2019 | |
| Amarin Pharma, INC. | $135.18 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $131.50 | 2019 | |
| Abbvie INC. | $109.64 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $103.91 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $86.80 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.09 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.25 | 2019 | |
| Novartis Pharmaceuticals Corporation | $68.03 | 2019 | |
| Daiichi Sankyo INC. | $42.10 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $41.94 | 2019 | |
| Sunovion Pharmaceuticals INC. | $38.00 | 2020-2021 | |
| Amgen INC. | $37.24 | 2019-2020 | |
| Astellas Pharma US INC | $32.24 | 2019 | |
| Avanir Pharmaceuticals, INC. | $27.31 | 2019 | |
| Genentech USA, INC. | $18.49 | 2019 | |
| Arbor Pharmaceuticals, INC. | $16.40 | 2019 | |
| Bausch Health US, LLC | $15.00 | 2019 | |
| Dermira, INC. | $13.90 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.08 | 2019 | |
| Circassia INC. | $13.07 | 2019 | |
| Boston Scientific Corporation | $12.46 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.30 | 2019 | |
| Allergan, INC. | $11.24 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Gramann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.